Look at the market cap and shares outstanding - that’s the albatross round the neck. A corporate train wreck ie cash runway fast diminishing IMO. From a clinical perspective they have a long, a very, very long way to go for approvals (years) and convincing US-based BIG PHARMA’s to partner with.
.
Add to My Watchlist
What is My Watchlist?
